The effect of helicobacter pylori eradication on macrophage migration inhibitory factor, c-reactive protein and fetuin-a levels

Clinics

Volumn 65, Issue 8, 2010, Pages 799-802

  Kebapcilar, Levent ^a   Bilgir, Oktay ^a   Cetinkaya, Elif ^a   Akyol, Murat ^a   Bilgir, Ferda ^a   Bozkaya, Giray ^a  

^a UNIVERSITY OF HEALTH SCIENCES   (Turkey)

Author keywords

Eradication; Fetuin a; Helicobacter pylori; High sensitivity c reactive protein; Macrophage migration inhibitory factor

Indexed keywords

EID: 77957698170     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322010000800010     Document Type: Article

References (29)

1. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet. 1997;350:430-6 doi: 10.1016/S0140-6736(97)03079-1.
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-95 doi: 10.1056/NEJMra043430.
3. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol. 2003;3:791-800. doi: 10.1038/nri1200.
4. Pakozdi A, Amin MA, Haas CS, Martinez RJ, Haines GK, 3rd, Santos LL, et al. Macrophage migration inhibitory factor: a mediator of matrix metalloproteinase-2 production in rheumatoid arthritis. Arthritis Res Ther. 2006;8:R132. doi: 10.1186/ar2021.
5. Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med. 2004;116(Suppl 6A):9S-16S. doi: 10.1016/j.amjmed.2004.02.006.
6. Blake GJ, Ridker PM. C-reactive protein: a surrogate risk marker or mediator of atherothrombosis? Am J Physaiol. 2003;285:R1250-R1252.
7. Wilson AM, Ryan MC, Boyle AJ. The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen. Int J Cardiol. 2006;106:291-7. doi: 10.1016/j.ijcard.2005.01.068.
8. Wang H, Zhang M, Bianchi M, Sherry B, Sama A, Tracey KJ. Fetuin (alpha2 - HS -glycoprotein) opsonizes cationic macrophage deactivating molecules. Proc Natl Acad Sci USA 1998;95:14429-34. doi: 10.1073/pnas.95.24.14429.
9. Demetriou M, Binkert C, Sukhu B, Tenenbaum HC, Dennis JW. Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist. J Biol Chem. 1996;271:12755-61. doi: 10.1074/jbc.271.22.12755.
10. Reynolds JL, Skepper JN, McNair R, Kasama T, Gupta K, Weissberg PL, et al. Multifunctional roles for serum protein fetuin-A in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol. 2005;16:2920-30. doi: 10.1681/ASN.2004100895.
11. Jafarzadeh A, Hassanshahi GH, Nemati M. Serum Levels of High- Sensitivity C-Reactive Protein (hs-CRP) in Helicobacter pylori-Infected Peptic Ulcer Patients and Its Association with Bacterial CagA Virulence Factor. Dig Dis Sci. 2009 Jan 22. [Epub ahead of print]
12. Stettin D, Waldmann A, Ströhle A, Hahn A. Association between Helicobacter pylori-infection, C-reactive protein and status of B vitamins. Adv Med Sci. 2008;53:205-13. doi: 10.2478/v10039-008-0050-8.
13. Kanbay M, Gür G, Yücel M, Yilmaz U, Boyacioǧlu S. Does eradication of Helicobacter pylori infection help normalize serum lipid and CRP levels? Dig Dis Sci. 2005;50:1228-31. doi: 10.1007/s10620-005-2764-9.
14. Beswick EJ, Pinchuk IV, Suarez G, Sierra JC, Reyes VE. Helicobacter pylori CagA-dependent macrophage migration inhibitory factor produced by gastric epithelial cells binds to CD74 and stimulates procarcinogenic events. J Immunol. 2006;176:6794-0801.
15. Xia HH, Lam SK, Chan AO, Lin MC, Kung HF, Ogura K, et al. Macrophage migration inhibitory factor stimulated by Helicobacter pylori increases proliferation of gastric epithelial cells. World J Gastroenterol. 2005;11:1946-50.
16. Ishiguro YT, Ohkawara H, Sakuraba K, Yamagata H, Hiraga S, Yamaguchi S, et al. Macrophage migration inhibitory factor has a proinflammatory activity via the p38 pathway in glucocorticoid-resistant ulcerative colitis. Clin. Immunol. 2006; 120335-341.
17. Mitchell RA, Liao J H, Chesney G, Fingerle-Rowson J, Baugh JD, Bucala R. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc. Natl. Acad. Sci. 2002; USA 99345-350.
18. Ren Y, Chan HM, Li Z, Lin C, Nicholls J, Chen CF, et al. Upregulation of macrophage migration inhibitory factor contributes to induced N-Myc expression by the activation of ERK signaling pathway and increased expression of interleukin-8 and VEGF in neuroblastoma. Oncogene. 2004; 23:4146-54. doi: 10.1038/sj.onc.1207490.
19. Beswick EJ, Reyes VE. CD74 in antigen presentation, inflammation, and cancers of the gastrointestinal tract. World J Gastroenterol. 2009;15:2855-61. doi: 10.3748/wjg.15.2855.
20. Bucala R, Donelly SC. Macrophage migration inhibitory factor: a probable link between inflammation and cancer. Immunity. 2007; 26:281-5. doi: 10.1016/j.immuni.2007.03.005.
21. Burger-Kentischer A, Goebel H, Seiler R, Fraedrich G, Schaefer HE, Dimmeler S, et al. Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation. 2002;105:1561-6. doi: 10.1161/01.CIR.0000012942.49244.82.
22. Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med. 2007;13:587-96. doi: 10.1038/nm1567.
23. Zernecke A, Shagdarsuren E, Weber C. Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol. 2008;28:1897-908. doi: 10.1161/ATVBAHA.107.161174.
24. Wang H, Zhang M, Soda K, Sama A, Tracey KJ. Fetuin protects the fetus from TNF. Lancet. 1997;350:861-2. doi: 10.1016/S0140-6736(05)62030-2.
25. Lord JM. A physiological role for alpha2-HS glycoprotein: stimulation of macrophage uptake of apoptotic cells. Clin Sci (Lond). 2003;105:267-8. doi: 10.1042/CS20030177.
26. Ombrellino M, Wang H, Yang H, Zhang M, Vishnubhakat J, Frazier A, et al. Fetuin, a negative acute phase protein, attenuates TNF synthesis and the innate inflammatory response to carrageenan. Shock.2001;15;181-5. doi: 10.1097/00024382-200115030-00004.
27. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Bohm R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a crosssectional study. Lancet. 2003;361:827-33. doi: 10.1016/S0140-6736(03)12710-9.
28. Stenvinkel P, Wang K, Qureshi AR, Axelsson J, Pecoits-Filho R, Gao P, et al. Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin. Kidney Int. 2005;67:2383-92. doi: 10.1111/j.1523-1755.2005.00345.x.
29. Koos R, Brandenburg V, Mahnken AH, Mühlenbruch G, Stanzel S, Günther RW, et al. Association of fetuin-A levels with the progression of aortic valve calcification in non-dialyzed patients. Eur Heart J. 2009;30:2054-61. doi: 10.1093/eurheartj/ehp158.